The identification of FOXO3a as a regulator of pyroptosis, along with the transactivating effect of FOXO3a on gene expression of cell cycle regulators, sheds light on new avenues and potential prognostic biomarkers for the therapy of patients with MDS. The gene discussed is FOXO3; the disease is myelodysplastic syndrome.